Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI technique may sharpen diagnosis of multiple sclerosis in older adults

NCT ID NCT07444047

Knowledge-focused Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can better tell apart brain lesions caused by multiple sclerosis (MS) from those due to normal aging or small vessel disease. Researchers will scan 1,000 people aged 50-70 with MS and compare them to a group with small vessel disease. The goal is to help doctors make more accurate diagnoses and treatment decisions for older adults with MS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of two cohorts recruited at Oslo University Hospital. The multiple sclerosis (MS) cohort includes participants aged 50-70 years with a clinically confirmed MS diagnosis enrolled in the AgeMS study, an ongoing longitudinal study of older individuals with MS. Eligible participants are invited to participate by letter. Participants undergo semiannual MRI examinations and standardized neurological, cognitive, and patient-reported assessments through 2030. The cerebral small vessel disease (cSVD) control cohort includes patients aged 50-80 years with radiological evidence of hypertensive small vessel disease identified on MRI and recruited from the Stroke Unit. Eligible participants are approached during hospital admission and invited to participate. Eligible participants are approached during hospital admission and invited to participate. These participants undergo a single MRI session and standardized clinical testing.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Multiple Sclerosis (MS) cohort (AgeMS): * Age 50-70 years * Clinically confirmed diagnosis of multiple sclerosis * Participation in the AgeMS study at Oslo University Hospital Inclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort: * Age 50-80 years * Radiological evidence of hypertensive small vessel disease on MRI * Good clinical recovery following transient ischemic attack (TIA), minor stroke, or stroke mimic diagnosis Exclusion Criteria Multiple Sclerosis (MS) cohort: * MRI contraindications * Severe psychiatric comorbidity * Major functional disability unrelated to MS or CSVD Exclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort: * MRI contraindications * Probable or definite cerebral amyloid angiopathy according to Boston criteria 2.0 * Genetic or inflammatory vasculopathies * Persistent neurological deficits * Severe psychiatric comorbidity * Major functional disability unrelated to CSVD

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral small vessel diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cerebral Small Vessel Diseases demyelinating disease multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral small vessel diseases Multiple sclerosis (MS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Oslo University Hospital

    RECRUITING

    Oslo, Oslo, 0450, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.